Teva CEO Explains 'Remarkable Story' Behind Guidance

Core Insights - Teva Pharmaceutical's stock experienced a significant decline due to unexpectedly low guidance for 2026, despite a strong performance in the fourth quarter [1] Financial Performance - For the upcoming year, Teva expects adjusted earnings per share to be between $2.57 and $2.77, with sales projected at $16.4 billion to $16.8 billion [1] - The earnings guidance is 16 cents lower than the midpoint expectation, indicating a shortfall in projected earnings [1] - The sales outlook did not meet market expectations, contributing to the stock's decline [1]